← Back to all trials
Recruiting
NCT06586047
Breast Cancer PSMA PET
Conditions: Triple Negative Breast Cancer
Sex: Female
Ages: 18 Years – 90 Years
Healthy volunteers: No
Phase: EARLY_PHASE1
Enrollment: 30
Sponsor: Ahmad Shariftabrizi
Location: University of Iowa Healthcare Iowa City Iowa
Summary
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Eligibility Criteria
Inclusion Criteria:
* Female \>= 18 years of age
* Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
* Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
Exclusion Criteria:
* Patients with known active other malignancy.
* Unable to tolerate PET/CT procedure.
* Pregnant or breastfeeding.
* Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Source: ClinicalTrials.gov (NCT06586047). StuddyBuddy aggregates publicly available trial information.
